Keywords: AstraZeneca, Brilinto, Plavix, Sanofi, Mortality benefit, ESC

AstraZeneca’s Brilinta shows mortality benefit over gold-standard Plavix

Article | 30 August 2011

Print This

There was good news for Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday, when the firm revealed positive results relating to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in